Nadav Kidron O r a m e d C E O

Fe a t u re d o n Fox B u s i n e s s

“ D i a b e t e s i s a r e a l e p i d e m i c . A l m o s t e v e r y o n e k n o w s

s o m e o n e t h a t s u ff e r s f r o m d i a b e t e s . A t t h e e n d o f t h e

d a y w h a t O r a m e d ’ s O r a l I n s u l i n o ff e r s t o p e o p l e i s …

n o t j u s t a n e a s i e r w a y t o a d m i n i s t e r i n s u l i n b e c a u s e

y o u w o n ’ t b e t a k i n g a n i n j e c t i o n .

I f we can de l i ve r insu l in o ra l l y then the pa t ient

wou ld use i t as an ear l i e r t reatment and i t w i l l he lp

them ba lance the d iabe tes in a much hea l th ie r way. ”

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

For More Information: http://www.oramed.com/